Andreas Pahl
Overview
Explore the profile of Andreas Pahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2998-3012.
PMID: 39440991
ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV...
2.
Wehrmuller J, Frei J, Hechler T, Kulke M, Pahl A, Behe M, et al.
Chembiochem
. 2024 Sep;
:e202400511.
PMID: 39305147
Homogeneous, site-specifically conjugated antibodies have shown to result in antibody-drug conjugates (ADCs) with improved efficacy and tolerability compared to stochastically conjugated ADCs. However, precisely controlling the drug load as well...
3.
Singh R, Jones R, Shirazi F, Qin L, Zou J, Hong S, et al.
Res Sq
. 2024 Jan;
PMID: 38260385
B-cell maturation antigen (BCMA) plays a pathobiologic role in myeloma and is a validated target with five BCMA-specific therapeutics having been approved for relapsed/refractory disease. However, these drugs are not...
4.
Vaisitti T, Vitale N, Micillo M, Brandimarte L, Iannello A, Papotti M, et al.
Blood
. 2022 Aug;
140(13):1565-1569.
PMID: 35914223
No abstract available.
5.
Yao G, Knittel C, Kosol S, Wenz M, Keller B, Gruss H, et al.
J Am Chem Soc
. 2021 Aug;
143(35):14322-14331.
PMID: 34459587
Synthetic methods on the macrocyclization of peptides are of high interest since they facilitate the synthesis of various types of potentially bioactive compounds, e.g. addressing targets like protein-protein-interactions. Herein, we...
6.
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, et al.
Nature
. 2021 Aug;
597(7875):E6.
PMID: 34433970
No abstract available.
7.
Zhang Z, Li H, Deng Y, Schuck K, Raulefs S, Maeritz N, et al.
Gastroenterology
. 2021 Jul;
161(5):1601-1614.e23.
PMID: 34303658
Background & Aims: Promoted by pancreatitis, oncogenic Kras triggers acinar cells' neoplastic transformation through acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia. Anterior gradient 2 (Agr2), a known inhibitor of p53,...
8.
Matinkhoo K, Wong A, Hambira C, Kato B, Wei C, Muller C, et al.
Chemistry
. 2021 May;
27(40):10282-10292.
PMID: 34058032
Alpha-amanitin, an extremely toxic bicyclic octapeptide extracted from the death-cap mushroom, Amanita phalloides, is a highly selective allosteric inhibitor of RNA polymerase II. Following on growing interest in using this...
9.
Gallo F, Korsak B, Muller C, Hechler T, Yanakieva D, Avrutina O, et al.
J Med Chem
. 2021 Mar;
64(7):4117-4129.
PMID: 33755471
Herein we describe the design and biological evaluation of a novel antitumor therapeutic platform that combines the most favorable properties of small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs)....
10.
Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, et al.
Sci Transl Med
. 2021 Feb;
13(580).
PMID: 33568521
The clinical challenge for treating HER2 (human epidermal growth factor receptor 2)-low breast cancer is the paucity of actionable drug targets. HER2-targeted therapy often has poor clinical efficacy for this...